Total Lesion Glycolysis on 18F-FDG PET/CT Is a Better Prognostic Factor Than Tumor Dose on 90Y PET/CT in Patients With Hepatocellular Carcinoma Treated With 90Y Transarterial Radioembolization
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Total Lesion Glycolysis on 18F-FDG PET/CT Is a Better Prognostic Factor Than Tumor Dose on 90Y PET/CT in Patients With Hepatocellular Carcinoma Treated With 90Y Transarterial Radioembolization
Authors
Keywords
-
Journal
CLINICAL NUCLEAR MEDICINE
Volume 47, Issue 6, Pages e437-e443
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2022-04-06
DOI
10.1097/rlu.0000000000004128
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization
- (2020) Jae Seung Lee et al. Gut and Liver
- The critical role of glucose deprivation in epithelial-mesenchymal transition in hepatocellular carcinoma under hypoxia
- (2020) Hanhee Jo et al. Scientific Reports
- Predicting tumor recurrence using metabolic indices of 18F‑FDG PET/CT prior to orthotopic liver transplantationfor hepatocellular carcinoma
- (2020) Enci Ding et al. Oncology Letters
- Relationship of Tumor Radiation–absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with 90Y in the SARAH Study
- (2020) Anne-Laure Hermann et al. RADIOLOGY
- Metabolic activity assessment by 18F‐FDG PET in patients with hepatocellular carcinoma undergoing Yttrium‐90 TARE
- (2020) Do Young Kim et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Prognostic value of imaging-based parameters in patients with intermediate-stage hepatocellular carcinoma undergoing transarterial radioembolization
- (2020) Ameya D. Puranik et al. NUCLEAR MEDICINE COMMUNICATIONS
- Radioembolization with 90Y glass microspheres for hepatocellular carcinoma: significance of pretreatment 11C-acetate and 18F-FDG PET/CT and posttreatment 90Y PET/CT in individualized dose prescription
- (2018) Chi Lai Ho et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Radioembolization for hepatocellular carcinoma: Statistical confirmation of improved survival in responders by landmark analyses
- (2018) Ahsun Riaz et al. HEPATOLOGY
- Anatomic versus Metabolic Tumor Response Assessment after Radioembolization Treatment
- (2018) Jennifer M.J. Jongen et al. JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- 18F-FDG PET/CT predicts survival after 90Y transarterial radioembolization in unresectable hepatocellular carcinoma
- (2017) Mario Jreige et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Volumetric parameters on FDG PET can predict early intrahepatic recurrence-free survival in patients with hepatocellular carcinoma after curative surgical resection
- (2017) Jeong Won Lee et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial
- (2017) Valérie Vilgrain et al. LANCET ONCOLOGY
- Signature of survival: a 18F-FDG PET based whole-liver radiomic analysis predicts survival after 90Y-TARE for hepatocellular carcinoma
- (2017) Paul Blanc-Durand et al. Oncotarget
- Increased 18F-FDG Uptake on PET/CT is Associated With Poor Arterial and Portal Perfusion on Multiphase CT
- (2016) Sang Hyun Hwang et al. CLINICAL NUCLEAR MEDICINE
- Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma
- (2016) Riad Salem et al. GASTROENTEROLOGY
- Prediction of Posttransplantation Recurrence of Hepatocellular Carcinoma Using Metabolic and Volumetric Indices of 18F-FDG PET/CT
- (2016) Y.-i. Kim et al. JOURNAL OF NUCLEAR MEDICINE
- Risk stratification for locally advanced hepatocellular carcinoma using pretreatment alpha-foetoprotein and18F-fluoro-2-deoxyglucose positron emission tomography
- (2016) Woo Joong Rhee et al. LIVER INTERNATIONAL
- Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization
- (2016) Yazan Abuodeh et al. WORLD JOURNAL OF GASTROENTEROLOGY
- The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis
- (2015) Jeong Won Lee et al. ANNALS OF NUCLEAR MEDICINE
- PET/CT-Based Dosimetry in 90Y-Microsphere Selective Internal Radiation Therapy
- (2015) Yoo Sung Song et al. MEDICINE
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2015) et al. JOURNAL OF HEPATOLOGY
- Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative 18F-FDG PET/CT in Patients with Pancreatic Cancer
- (2014) J. W. Lee et al. JOURNAL OF NUCLEAR MEDICINE
- Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis
- (2014) Annagiulia Gramenzi et al. LIVER INTERNATIONAL
- Prognostic Importance of 18F-FDG Uptake Pattern of Hepatocellular Cancer Patients Who Received SIRT
- (2013) Ozlem N. Kucuk et al. CLINICAL NUCLEAR MEDICINE
- 18F-Fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma
- (2013) Myeong Jun Song et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma
- (2013) ZHIHONG WENG et al. Oncology Letters
- 18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma
- (2011) Beom Kyung Kim et al. CANCER
- Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer
- (2011) Shengri Liao et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation
- (2011) Bruno Sangro et al. HEPATOLOGY
- Usefulness of Positron Emission Tomography With Fluorine-18-Fluorodeoxyglucose in Predicting Treatment Response in Unresectable Hepatocellular Carcinoma Patients Treated With External Beam Radiotherapy
- (2011) Jun Won Kim et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Imaging characteristics following 90yttrium microsphere treatment for unresectable liver cancer
- (2011) Lourens Bester et al. Journal of Medical Imaging and Radiation Oncology
- Patients with non-[18F]fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation
- (2011) Arno Kornberg et al. LIVER TRANSPLANTATION
- Radioembolization Results in Longer Time-to-Progression and Reduced Toxicity Compared With Chemoembolization in Patients With Hepatocellular Carcinoma
- (2010) Riad Salem et al. GASTROENTEROLOGY
- Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer
- (2010) Hyun Hoon Chung et al. GYNECOLOGIC ONCOLOGY
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started